other material
confidence high
sentiment neutral
materiality 0.50
Cogent Biosciences exchanges 8.3M common shares for Series B non-voting convertible preferred
Cogent Biosciences, Inc.
- 8,300,000 common shares exchanged for 8,300 Series B Preferred convertible into 20,580,000 common shares.
- Exchange closes March 25, 2024; Series B has no voting rights except on amendments to its preferences.
- Post-exchange common outstanding: 95,613,396; Series A Preferred convertible into 18,616,250 common shares.
- Issued under Section 3(a)(9) exemption; no registration required.